Community Series in Reducing Adverse Effects of Cancer Immunotherapy: Volume II

12k
Total downloads
43k
Total views and downloads

Articles

ORIGINAL RESEARCH

Accepted on 11 Aug 2025

Emerging Causes of Anticancer Therapies-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Evidence from Disproportionality Analysis of the FDA Adverse Event Reporting System

Wensheng Liu
Xue Song
Qiong Du
Jiyong Liu

doi 10.3389/fimmu.2025.1646038

173 views

REVIEW

Published on 21 May 2025

Leveraging immune checkpoint inhibitors in lung cancer patients with pre-existing autoimmune disease: clinical insights, optimal timing, and predictive biomarkers for optimal treatment outcomes

Hui Yang
Sheng Yu
Hong Ge

doi 10.3389/fimmu.2025.1539260

1,678 views

SYSTEMATIC REVIEW

Published on 21 May 2025

Risk factors for checkpoint inhibitor pneumonitis in lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis

Xiaoqing Zhou
Yingnan Xu
Yuanyuan Ying
Ruilin Chen
Zhen Wang
Xin Lv

doi 10.3389/fimmu.2025.1607170

2,810 views

ORIGINAL RESEARCH

Published on 16 Apr 2025

Differences in the count of blood cells pre-and post-chemotherapy in patients with cancer: a retrospective study (2022)

Tadele Derbew Kassie
Bayu Wondimneh Yimenu
Gelagey Baye Temesgen
Rahel Asres Shimelash
Aysheshim Asnake Abneh

doi 10.3389/fmed.2025.1485676

1,357 views
1 citation

ORIGINAL RESEARCH

Published on 27 Jan 2025

Impact of chemoradiotherapy for first primary lung cancer on the prognosis and re-chemoradiotherapy sensitivity of second primary lung cancer

Zhe Chen
Gaoming Wang
Nan Wang
Jiangjiang Liu
Yu Yao
Haitao Ma
Jing Luo
Kai Xie

doi 10.3389/fimmu.2025.1492501

1,197 views

CASE REPORT

Published on 23 Jan 2025

Sintilimab for the treatment of lung adenocarcinoma-induced immune-related hypophysitis: a case report

Ming-xing Wang
Ai-xin Liu
Qing-ming Sun
Wan-hui Dong

doi 10.3389/fimmu.2025.1534179

1,018 views
2 citations

CASE REPORT

Published on 23 Dec 2024

Immune-related adverse events with renal colic as the main manifestation: a case report of sintilimab-induced ureteritis/cystitis treated by ureteral stent and review of the literature

Jiaxiang Ji
Chin-Hui Lai
Xiaowei Zhang
Hao Hu

doi 10.3389/fimmu.2024.1501415

1,383 views
3 citations

ORIGINAL RESEARCH

Published on 17 Dec 2024

Ocular adverse events associated with antibody-drug conjugates: a comprehensive pharmacovigilance analysis

Heng Chen
Gefei He
Juanjuan Huang
Lin Hu
Junlong Ma

doi 10.3389/fimmu.2024.1495137

4,082 views
3 citations

ORIGINAL RESEARCH

Published on 08 Oct 2024

Association between statin use and immune-related adverse events in patients treated with immune checkpoint inhibitors: analysis of the FAERS database

Huaju Yang
Rendong Huang
Ping Zhang
Yingtong Liu
Zheran Liu
Jiagang He
Xingchen Peng

doi 10.3389/fimmu.2024.1439231

2,997 views
4 citations

CASE REPORT

Published on 30 Sep 2024

Case report: Fatal hemoptysis after effective treatment with tislelizumab and anlotinib in pulmonary sarcomatoid carcinoma

Chen-Wei Pu
Yong-Fen Ma
Jing-Jing Peng
Zhen-Zhen Wang

doi 10.3389/fonc.2024.1445358

1,235 views
1 citation

CASE REPORT

Published on 16 Sep 2024

Sintilimab-induced myocarditis suspected in a patient with esophageal cancer and followed septic shock: case report and literature review

Qihao Zhou
Zhiquan Qin
Guoqing Wu
Peiyuan Yan
Qunjiang Wang
Jing Qu
Jiahong Jiang

doi 10.3389/fonc.2024.1465395

1,432 views
3 citations

BRIEF RESEARCH REPORT

Published on 24 Jul 2024

Relationship between nausea and vomiting and physical activity in patients with lung cancer undergoing first chemotherapy

Liandi Bai
Li Ni
JianHong Lu
Yue Yu Zhang
Yuanyuan Yin
WeiYing Zhang
Xia Duan

doi 10.3389/fonc.2024.1396637

1,608 views
3 citations

Share on

Frontiers in Immunology

Cancer Immunity and Immunotherapy
Inflammation

Participating Journals

Frontiers in Oncology
- Cancer Immunity and Immunotherapy
- 3.3 impact factor
- 6.9 citescore

Impact

43kTopic views
30kArticle views
12kArticle downloads

View impact

Articles

Emerging Causes of Anticancer Therapies-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Evidence from Disproportionality Analysis of the FDA Adverse Event Reporting System

Leveraging immune checkpoint inhibitors in lung cancer patients with pre-existing autoimmune disease: clinical insights, optimal timing, and predictive biomarkers for optimal treatment outcomes

Risk factors for checkpoint inhibitor pneumonitis in lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis

Differences in the count of blood cells pre-and post-chemotherapy in patients with cancer: a retrospective study (2022)

Impact of chemoradiotherapy for first primary lung cancer on the prognosis and re-chemoradiotherapy sensitivity of second primary lung cancer

Sintilimab for the treatment of lung adenocarcinoma-induced immune-related hypophysitis: a case report

Immune-related adverse events with renal colic as the main manifestation: a case report of sintilimab-induced ureteritis/cystitis treated by ureteral stent and review of the literature

Ocular adverse events associated with antibody-drug conjugates: a comprehensive pharmacovigilance analysis

Association between statin use and immune-related adverse events in patients treated with immune checkpoint inhibitors: analysis of the FAERS database

Case report: Fatal hemoptysis after effective treatment with tislelizumab and anlotinib in pulmonary sarcomatoid carcinoma

Sintilimab-induced myocarditis suspected in a patient with esophageal cancer and followed septic shock: case report and literature review

Relationship between nausea and vomiting and physical activity in patients with lung cancer undergoing first chemotherapy

Frontiers in Immunology

Cancer Immunity and Immunotherapy

Inflammation

Participating Journals

Frontiers in Oncology

Cancer Immunity and Immunotherapy